ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

December 9, 2005

PET Better At Evaluating Response In Sarcoma

February 29, 2008

FDA Describes Meeting With NCI In “Limited” Memo

May 7, 1976

Treanda Approved For B-Cell Non-Hodgkin’s Lymphoma

October 31, 2008

In Phase II Study, Vaccine IMA910 Stimulated Immune Response

February 24, 2012

In Brief: NCI To File Heroin IND For Pain Control; Sen. Cranston To Keynote Meeting On Centers

March 31, 1978